Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy

References

• Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290–293.
   PubMed Web of Science ®Google Scholar
• Goldman J, Melo J. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1084–1086.
   PubMed Web of Science ®Google Scholar
• Druker B, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561–566.
   PubMed Web of Science ®Google Scholar
• Bhamidipati P, Kantarjian H, Cortes J, et al. Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol. 2013;4(2):103–117.
   PubMedGoogle Scholar
• Hochhaus A, La Rosee P, Muller M, et al. Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. Cell Cycle. 2011;10(2):250–260.
   PubMed Web of Science ®Google Scholar
• Molica M, Massaro F, Breccia M. Second line small molecule therapy options for treating chronic myeloid leukemia. Expert Opin Pharmacother. 2017;18(1):57–65.
   PubMed Web of Science ®Google Scholar
• Pophali P, Patnaik M. The role of new tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer J. 2016;22(1):40–50.
   PubMed Web of Science ®Google Scholar
• Holyoake T, Vetrie D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood. 2017;129(12):1595–1606.
   PubMed Web of Science ®Google Scholar
• Zabriskie M, Vellore N, Gantz K, et al. Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1. Leukemia. 2015;29(9):1939–1942.
   PubMed Web of Science ®Google Scholar
• Lee J, Han B, Goh H, et al. IY551, a novel BCR-ABL tyrosine kinase inhibitor, is highly active compound in inhibition of CrkL phosphorylation and in xenograft animal chronic myeloid leukemia model. ISH-APD APBMT Abst. 2007;02–061.
   Google Scholar
• Lee J, Kim H, Sohn S, et al. Safety and efficacy of radotinib, a tyrosine kinase inhibitor. Korean J Hematol. 2011;46(Suppl. 2):152.
   PubMedGoogle Scholar
• Kim S, Menon H, Jootar S, et al. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Haematologica. 2014;99(7):1191–1196.
   PubMed Web of Science ®Google Scholar
• Kim S, Menon H, Jootar S, et al. Radotinib treatment in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 TKIs: 36 months update of radotinib phase 2 study. EHA Abst. 2017;102(s2):E1062.
   Google Scholar
• Kwak J, Kim S, Oh S, et al. Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia. Clin Cancer Res. 2017;23(23):7180–7188.
   PubMed Web of Science ®Google Scholar
• Experts in chronic myeloid leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22):4439–4442.
   PubMed Web of Science ®Google Scholar
• Wylie A, Schoepfer J, Jahnke W, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543(7647):733–737.
   PubMed Web of Science ®Google Scholar
• Hughes T, Goh YT, Ottmann O, et al. Expanded phase 1 study of ABL001, a potent, allosteric inhibitor of BCR-ABL, reveals significant and durable responses in patients with CML-chronic phase with failure of prior TKI therapy. Blood. 2016;128:625.
   PubMed Web of Science ®Google Scholar
• Gontarewicz A, Balabanov S, Keller G, et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood. 2008;111(8):4355–4364.
   PubMed Web of Science ®Google Scholar
• Borthakur G, Dombret H, Schafhausen P, et al. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica. 2015;100(7):898–904.
   PubMed Web of Science ®Google Scholar
• Chan W, Wise S, Kaufman M, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. 2011;19(4):556–568.
   PubMed Web of Science ®Google Scholar
• Cortes J, Talpaz M, Smith H, et al. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica. 2017;102(3):519–528.
   PubMed Web of Science ®Google Scholar
• Müller M, Cervantes F, Hjorth-Hansen H, et al. Ponatinib in chronic myeloid leukemia (CML): consensus on patient treatment and management from a European expert panel. Crit Rev Oncol Hematol. 2017;120:52–59.
   PubMed Web of Science ®Google Scholar
• Ravegnini G, Sammarini G, Angelini S, et al. Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia. Expert Opin Drug Metab Toxicol. 2016;12(7):733–742.
   PubMed Web of Science ®Google Scholar
• Qiang W, Antelope O, Zabriskie M, et al. Mechanism of resistance to the BCR-ABL1 allosteric inhibitor asciminib. Leukemia. 2017;31(12):2844–2847.
   PubMed Web of Science ®Google Scholar
• Elsayed A, Srivastava R, Jamil M. Treatment-free remission: a new therapeutic goal in chronic myelogenous leukemia. Curr Oncol Rep. 2017;19(12):77.
   PubMed Web of Science ®Google Scholar
• Hughes A, Yong A. Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front Immunol. 2017;8:469.
   PubMed Web of Science ®Google Scholar
• Nath A, Wang J, Stephanie Huang R. Pharmacogenetics and pharmacogenomics of targeted therapeutics in chronic myeloid leukemia. Mol Diagn Ther. 2017;21(6):621–631.
   PubMed Web of Science ®Google Scholar
• Patel A, O’Hare T, Deininger M. Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors. Hematol Oncol Clin North Am. 2017;31(4):589–612.
   PubMed Web of Science ®Google Scholar
• Gallipoli P, Cook A, Rhodes S, et al. JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. Blood. 2014;124(9):1492–1501.
   PubMed Web of Science ®Google Scholar
• Prost S, Relouzat F, Spentchian M, et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPARϒ agonists. Nature. 2015;525(7569):380–383.
   PubMed Web of Science ®Google Scholar
• Mahon F, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–1035.
   PubMed Web of Science ®Google Scholar
• Ross D, Branford S, Seymour J, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515–522.
   PubMed Web of Science ®Google Scholar
• Dulucq S, Mahon F. Deep molecular responses for treatment-free remission in chronic myeloid leukemia. Cancer Med. 2016;5(9):2398–2411.
   PubMed Web of Science ®Google Scholar
• Zhang B, Li M, McDonald T, et al. Microenvironmental protection of CML stem and progenitor cellsfrom tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signalling. Blood. 2013;121(10):1824–1838.
   PubMed Web of Science ®Google Scholar
• Bellodi C, Lidonnici M, Hamilton A, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest. 2009;119(5):1109–1123.
   PubMed Web of Science ®Google Scholar
• Avgustinova A, Benitah SA. The epigenetics of tumour initiation: cancer stem cells and their chromatin. Curr Opin Genet Dev. 2016;36:8–15.
   PubMed Web of Science ®Google Scholar